6EWA
| Crystal structure of HLA-A2 in complex with LILRB1 | 分子名称: | Beta-2-microglobulin, HLA class I histocompatibility antigen, A-2 alpha chain, ... | 著者 | Stones, D.H, Willcox, B.E, Mohammed, F. | 登録日 | 2017-11-03 | 公開日 | 2018-11-07 | 最終更新日 | 2024-11-13 | 実験手法 | X-RAY DIFFRACTION (2.39 Å) | 主引用文献 | Application of the immunoregulatory receptor LILRB1 as a crystallisation chaperone for human class I MHC complexes. J. Immunol. Methods, 464, 2019
|
|
6EWO
| Crystal structure of non-phosphorylated form of RTF PHOSPHOPEPTIDE BOUND TO HLA-A2 in complex with LILRB1 | 分子名称: | Beta-2-microglobulin, HLA class I histocompatibility antigen, A-2 alpha chain, ... | 著者 | Mohammed, F, Stones, D.H, Willcox, B.E. | 登録日 | 2017-11-06 | 公開日 | 2018-11-07 | 最終更新日 | 2024-11-13 | 実験手法 | X-RAY DIFFRACTION (2.3 Å) | 主引用文献 | Application of the immunoregulatory receptor LILRB1 as a crystallisation chaperone for human class I MHC complexes. J. Immunol. Methods, 464, 2019
|
|
6EWC
| Crystal structure of non-phosphorylated form of RLS PHOSPHOPEPTIDE BOUND TO HLA-A2 in complex with LILRB1 | 分子名称: | Beta-2-microglobulin, HLA class I histocompatibility antigen, A-2 alpha chain, ... | 著者 | Mohammed, F, Stones, D.H, Willcox, B.E. | 登録日 | 2017-11-03 | 公開日 | 2018-11-07 | 最終更新日 | 2024-11-06 | 実験手法 | X-RAY DIFFRACTION (3.2 Å) | 主引用文献 | Application of the immunoregulatory receptor LILRB1 as a crystallisation chaperone for human class I MHC complexes. J. Immunol. Methods, 464, 2019
|
|
4NO0
| Crystal structure of non-phosphorylated form of RQA_V phosphopeptide bound to HLA-A2 in complex with LILRB1 | 分子名称: | 1,2-ETHANEDIOL, Beta-2-microglobulin, HLA class I histocompatibility antigen, ... | 著者 | Mohammed, F, Stones, D.H, Willcox, B.E. | 登録日 | 2013-11-19 | 公開日 | 2014-11-19 | 最終更新日 | 2023-09-20 | 実験手法 | X-RAY DIFFRACTION (2.7 Å) | 主引用文献 | The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status. Oncotarget, 8, 2017
|
|
4NO3
| Crystal structure of AMPD2 phosphopeptide bound to HLA-A2 | 分子名称: | 1,2-ETHANEDIOL, AMP deaminase 2, Beta-2-microglobulin, ... | 著者 | Mohammed, F, Stones, D.H, Willcox, B.E. | 登録日 | 2013-11-19 | 公開日 | 2014-12-24 | 最終更新日 | 2024-10-30 | 実験手法 | X-RAY DIFFRACTION (1.703 Å) | 主引用文献 | The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status. Oncotarget, 8, 2017
|
|
4NO5
| Crystal structure of non-phosphorylated form of AMPD2 phosphopeptide bound to HLA-A2 | 分子名称: | 1,2-ETHANEDIOL, AMP deaminase 2, Beta-2-microglobulin, ... | 著者 | Mohammed, F, Stones, D.H, Willcox, B.E. | 登録日 | 2013-11-19 | 公開日 | 2014-12-24 | 最終更新日 | 2024-10-30 | 実験手法 | X-RAY DIFFRACTION (2.101 Å) | 主引用文献 | The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status. Oncotarget, 8, 2017
|
|
4NNY
| Crystal structure of non-phosphorylated form of PKD2 phosphopeptide bound to HLA-A2 | 分子名称: | Beta-2-microglobulin, CADMIUM ION, GLYCEROL, ... | 著者 | Mohammed, F, Stones, D.H, Willcox, B.E. | 登録日 | 2013-11-19 | 公開日 | 2014-11-19 | 最終更新日 | 2023-09-20 | 実験手法 | X-RAY DIFFRACTION (1.9 Å) | 主引用文献 | The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status. Oncotarget, 8, 2017
|
|
4NO2
| Crystal structure of RQA_V phosphopeptide bound to HLA-A2 | 分子名称: | 1,2-ETHANEDIOL, Beta-2-microglobulin, HLA class I histocompatibility antigen, ... | 著者 | Mohammed, F, Stones, D.H, Willcox, B.E. | 登録日 | 2013-11-19 | 公開日 | 2014-11-19 | 最終更新日 | 2024-11-06 | 実験手法 | X-RAY DIFFRACTION (2 Å) | 主引用文献 | The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status. Oncotarget, 8, 2017
|
|
4NNX
| Crystal structure of PKD2 phosphopeptide bound to HLA-A2 | 分子名称: | Beta-2-microglobulin, CADMIUM ION, GLYCEROL, ... | 著者 | Mohammed, F, Stones, D.H, Willcox, B.E. | 登録日 | 2013-11-19 | 公開日 | 2014-11-19 | 最終更新日 | 2024-10-09 | 実験手法 | X-RAY DIFFRACTION (2.104 Å) | 主引用文献 | The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status. Oncotarget, 8, 2017
|
|